CompletedPhase 3

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

China315 participantsStarted 2022-03-25

Plain-language summary

This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects voluntarily sign the informed consent form. * Patients who participated in ZGJAK018. Exclusion Criteria: * Subjects who are unsuitable to the trial, as identified by the investigator.

What they're measuring

Number of subjects reporting treatment-emergent adverse events

Timeframe: Baseline through week 24

Trial details

NCT IDNCT05255237

SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-06-28

View on ClinicalTrials.gov More Alopecia Areata trials